Glycoprotein

Glycoprotein designates proteins with covalently attached carbohydrate chains added through post-translational modification, representing the most abundant modified protein class in nature and encompassing the majority of therapeutic biologics including monoclonal antibodies, cytokines, hormones, and enzymes. Glycoprotein characterisation proves essential for biopharmaceutical development given glycan heterogeneity affecting product consistency and therapeutic performance.

The pharmaceutical industry extensively characterises and controls glycoprotein therapeutics throughout development and manufacturing. Glycosylation patterns depend on host cell type, culture conditions, and biosynthetic pathway expression, requiring careful manufacturing control. Therapeutic antibody glycosylation critically affects effector functions, with Fc glycan modifications modulating antibody-dependent cellular cytotoxicity and complement activation. Biosimilar development requires comprehensive glycan comparability demonstrating similarity to reference products. Regulatory submissions include detailed glycan characterisation with batch-to-batch consistency data and specifications ensuring product quality. Manufacturing optimisation manages glycosylation through cell line selection, media composition, and process parameters.